FDA Approves Breztri Triple Therapy for Asthma Maintenance
Overview
The FDA has approved budesonide/glycopyrrolate/formoterol fumarate (Breztri) as a fixed-dose triple-combination inhaler for maintenance treatment of asthma in patients aged 12 and older. Phase 3 trials demonstrated significant improvements in lung function compared to dual therapy, with rapid onset and no new safety concerns.
Background
Asthma affects approximately 27 million people in the US, with about half remaining uncontrolled despite dual maintenance therapies. Persistent airway inflammation and bronchoconstriction cause symptoms such as wheezing, dyspnea, chest tightness, and frequent exacerbations. Current dual therapies often fail to fully control symptoms or prevent attacks, highlighting the need for more effective maintenance options. Breztri combines an inhaled corticosteroid, a long-acting beta2-agonist, and a long-acting muscarinic antagonist in a single inhaler.
Data Highlights
| Parameter | Outcome | Timeframe |
|---|---|---|
| Forced Expiratory Volume in 1 second (FEV1) | Improved over ICS/LABA therapy | First 3 hours at 24 weeks |
| Trough Lung Function | Improved | 12 to 24 weeks and at 24 weeks |
| Onset of Action | Improvement within 5 minutes of initial dose | Initial dosing |
| Patient Population | ~4,300 randomized patients with asthma | Phase 3 KALOS and LOGOS trials |
Key Findings
- FDA approved Breztri (budesonide/glycopyrrolate/formoterol fumarate) for asthma maintenance in patients ≥12 years old.
- Phase 3 KALOS and LOGOS trials included ~4,300 patients with and without recent exacerbations.
- Triple therapy improved lung function (FEV1) significantly compared to ICS/LABA dual therapy.
- Rapid onset of action observed with lung function improvement within 5 minutes of first dose.
- No new safety or tolerability issues identified during trials.
- Therapy is for maintenance use only and not intended for acute bronchospasm relief.
Clinical Implications
Breztri offers a new maintenance treatment option for asthma patients inadequately controlled on dual therapy, potentially reducing exacerbations and improving daily lung function. Its rapid onset and triple mechanism may enhance symptom control and patient adherence. Clinicians should note it is not a rescue inhaler and should be used as part of a long-term management plan.
Conclusion
The FDA approval of Breztri expands therapeutic options for asthma maintenance, providing improved lung function and rapid symptom control without new safety concerns. This triple-combination inhaler addresses unmet needs in patients inadequately controlled on existing dual therapies.
Related Resources & Content
- AstraZeneca 2024 -- FDA Clears Breztri for Asthma Use
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
